Passive Prescription of Secondary Prevention Medical Therapy during Index Hospitalization for Acute Myocardial Infarction Is Prevalent and Associated with Adverse Clinical Outcomes

Secondary prevention therapy reduces death and reinfarction after acute myocardial infarction (AMI), but it is underutilized in clinical practice. Mechanisms for this therapeutic gap are not well established. In this study, we have explored and evaluated the impact of passive continuation compared to active initiation of secondary prevention therapy for AMI during the index hospitalization. For this purpose, we have analyzed 1083 consecutive patients with AMI to a tertiary referral hospital in Hong Kong and assessed discharge prescription rates of secondary prevention therapies (aspirin, beta-blockers, statins, and ACEI/ARBs). Multivariate analysis was used to identify independent predictors of discharge medication, and Kaplan–Meier survival curve was used to evaluate 12-month survival. Overall, prescription rates of aspirin, beta-blocker, statin, and ACEI/ARBs on discharge were 94.8%, 64.5%, 83.5%, and 61.4%, respectively. Multivariate analysis showed that prior use of each therapy was an independent predictor of prescription of the same therapy on discharge: aspirin (odds ratio (OR) = 4.8, 95% CI = 1.9–12.3, P < 0.01), beta-blocker (OR = 2.5, 95% CI = 1.8–3.4, P < 0.01); statin (OR = 8.3, 95% CI = 0.4–15.7, P < 0.01), and ACEI/ARBs (OR = 2.9, 95% CI = 2.0–4.3, P < 0.01). Passive continuation of prior medication was associated with higher 1-year mortality rates than active initiation in treatment-naïve patients (aspirin (13.7% vs. 5.7%), beta-blockers (12.9% vs. 5.6%), and statins (11.0% vs. 4.6%); all P < 0.01). Overall, the use of secondary prevention medication for AMI was suboptimal. Our findings suggested that the practice of passive continuation of prior medication was prevalent and associated with adverse clinical outcomes compared to active initiation of secondary preventive therapies for acute myocardial infarction during the index hospitalization.

[1]  H. Okano,et al.  Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages , 2020, Nature Communications.

[2]  Alan S. Go,et al.  Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction , 2020, Journal of the American Heart Association.

[3]  S. Akers,et al.  Serum Albumin Is a Marker of Myocardial Fibrosis, Adverse Pulsatile Aortic Hemodynamics, and Prognosis in Heart Failure With Preserved Ejection Fraction , 2020, Journal of the American Heart Association.

[4]  W. Maier,et al.  Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival , 2020, The European Journal of Health Economics.

[5]  S. Normand,et al.  Association Between Medication Adherence and 1‐Year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China , 2019, Journal of the American Heart Association.

[6]  D. McManus,et al.  Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction. , 2016, The American journal of cardiology.

[7]  Deepak L. Bhatt,et al.  Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction , 2015, Heart.

[8]  R. Holle,et al.  Secondary Prevention Medication After Myocardial Infarction: Persistence in Elderly People over the Course of 1 Year , 2014, Drugs & Aging.

[9]  V. Lee,et al.  Cost‐Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation—A Real Patient Data Analysis in a Hong Kong Teaching Hospital , 2013, Clinical Cardiology.

[10]  A. Coats,et al.  Albumin levels predict survival in patients with heart failure and preserved ejection fraction , 2012, European journal of heart failure.

[11]  H. Quan,et al.  Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients , 2011, BMC cardiovascular disorders.

[12]  P. Davidson,et al.  Lost in Translation: Health Resource Variability in the Achievement of Optimal Performance and Clinical Outcome , 2011, Circulation. Cardiovascular quality and outcomes.

[13]  Pierre Ambrosi,et al.  Human serum albumin in the clinical syndrome of heart failure. , 2011, Journal of cardiac failure.

[14]  C. Cannon,et al.  Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly: Findings From the Get With the Guidelines Quality-Improvement Program , 2009, Circulation. Cardiovascular quality and outcomes.

[15]  P. Phillips,et al.  Unperceived treatment gaps in acute coronary syndromes , 2009, International journal of clinical practice.

[16]  Deepak L. Bhatt,et al.  Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease: Results From the Get With the Guidelines Program , 2009, Circulation.

[17]  A. Yan,et al.  Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. , 2007, American heart journal.

[18]  R. Califf,et al.  The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. , 2006, American heart journal.

[19]  Jiang He,et al.  Major causes of death among men and women in China. , 2005, The New England journal of medicine.

[20]  C. Mueller,et al.  Hepatic proteins and nutrition assessment. , 2004, Journal of the American Dietetic Association.

[21]  J. Gore,et al.  From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). , 2003, European heart journal.

[22]  K. Pearson.  Guideline‐discordant care in acute myocardial infarction: predictors and outcomes , 2002, The Medical journal of Australia.

[23]  Á. Avezum,et al.  Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE) , 2002, The Lancet.

[24]  H. Krumholz,et al.  ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-eleva , 2008, Circulation.